The present invention relates to a pyrroloquinoline quinone derivative represented by formula I or a pharmaceutically acceptable salt thereof U, V, W, X, Y and Z are each independently valued as an atom selected from among C, N, O, and S, and are linked together to form a substitute aromatic or non-aromatic ring, the conditions being that U is not an O or S atom and that U, V, W, X, Y, and Z satisfy the valence requirements of the respective valued atoms, the part that is not sufficient forming a bond with a hydrogen atom to compensate. The pyrroloquinoline quinone derivative or a pharmaceutically acceptable salt thereof and a composition thereof have a significant anti-cancer effect, a treatment group having a higher drug concentration having more obvious anti-cancer efficiency the present invention may inhibit the growth activity of tumor cells up to 30%-80%, while the pyrroloquinoline quinone derivative represented by formula I of the present invention has good therapeutic effects on autoimmune diseases such as lupus, metabolic diseases such as type II diabetes and nonalcoholic fatty liver disease, neurodegenerative diseases such as Alzheimers disease, diseases caused by over-activity of inflammatory cells such as septic shock, and diseases caused by cellular immunotherapy, such as cytokine storms.La présente invention concerne un dérivé de pyrroloquinoléine quinone représenté par la formule I ou un sel de qualité pharmaceutique de celui-ci U, V, W, X, Y et Z représentent chacun indépendamment un atome choisi parmi C, N, O et S, et sont liés ensemble pour former un cycle aromatique ou non aromatique de substitution, sous réserve que U ne soit pas un atome de O ou de S et que U, V, W, X, Y et Z soient conformes aux exigences en termes de valence des atomes correspondants, la partie se révélant insuffisante formant une liaison avec un atome dhydrogène pour compenser. Le dérivé de pyrroloquinoléine quinone ou un sel de qualité pharmaceutique de celui-ci et une compo
